Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells

Pharmacology

Volumn 76, Issue 1, 2005, Pages 8-18

  Lob, Heinrich ^a   Rosenkranz, Anke Claudia ^a,b   Breitenbach, Thomas ^a   Berkels, Reinhard ^c   Drummond, Grant ^d   Roesen, Renate ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ACE inhibitors; Angiotensin ii; Bradykinin; Ca2+ channel antagonist; NADPH oxidase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMLODIPINE; ANGIOTENSIN; BRADYKININ; CAPTOPRIL; CHELERYTHRINE; CYTOCHROME C; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ICATIBANT; LUCIGENIN; NISOLDIPINE; NITRIC OXIDE; PHORBOL ESTER; PROTEIN KINASE C INHIBITOR; RAMIPRILAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RHODAMINE 123; SUPEROXIDE; UNCLASSIFIED DRUG;

AMPEROMETRIC BIOSENSOR; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL STIMULATION; CHEMOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME SUBUNIT; EXTRACELLULAR SPACE; FLUORESCENCE; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION KINETICS; REGULATORY MECHANISM; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CELL LINE; DIHYDROPYRIDINES; ENDOTHELIAL CELLS; HUMANS; NADPH OXIDASE; NITRIC OXIDE; PROTEIN KINASE C; SUPEROXIDES;

EID: 28744436699     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088854     Document Type: Article

References (52)

1. Zhang C, Hein TW, Wang W, Kuo L: Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322-329.
2. Hsu YH, Chen JJ, Chang NC, Chen CH, Liu JC, Chen TH, Jeng CJ, Chao HH, Cheng TH: Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells. J Vasc Res 2004;41:64-74.
3. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
4. Taubman MB: Angiotensin II: a vasoactive hormone with ever-increasing biological roles. Circ Res 2003;92:9-11.
5. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL: Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004;22:535-542.
6. Jiang F, Drummond GR, Dusting GJ: Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004;11:79-88.
7. Tieu K, Ischiropoulos H, Przedborski S: Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003;55:329-335.
8. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR: Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003;30:849-854.
9. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004;109:227-233.
10. Banfi B, Clark RA, Steger K, Krause KH: Two novel proteins activate speroxide generation by the NADPH oxidase NOX1. J Biol Chem 2003;278:3510-3513.
11. Lapouge K, Smith SJ, Groemping Y, Rittinger K: Architecture of the p40-p47-p67phox complex in the resting state of the NADPH oxidase: a central role for p67phox. J Biol Chem 2002;277:10121-10128.
12. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-3078.
13. Li JM, Shah AM: ROS generation by nonphagocytic NADPH oxidase: Potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003;14(suppl 3):S221-S226.
14. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20:2175-2183.
15. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
16. Li JM, Shall AM: Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002;277:19952-19960.
17. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000;86:E85-E90.
18. Berkels R, Taubert D, Rosenkranz A, Rosen R: Vascular protective effects of dihydropyridine calcium antagonists: involvement of endothelial nitric oxide. Pharmacology 2003;69:171-176.
19. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R: Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004;70:39-45.
20. Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003;29:147-152.
21. Breitenbach T, Bartels H, Berkels R, Klaus W, Roesen R: Antioxidative properties of dihydropyridin-calcium antagonists in comparison with ACE-inhibitors (abstract). Naunyn Schmiedebergs Arch Pharmacol 2003;367(suppl 1):R66.
22. Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, Asakura M, Sanada S, Kuzuya T, Hori M: Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000;101:311-317.
23. Asanuma H, Kitakaze M: Calcium channel blockers increasing coronary blood flow via NO-dependent mechanism. Nippon Rinsho 2004;62(suppl 9):567-572.
24. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA 1989;86:2388-2392.
25. Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, Luft FC, Haller H: Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation 1999;99:2523-2529.
26. Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I: Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003;59:844-853.
27. Asano Y, Kim J, Ogai A, Takashima S, Shintani Y, Minamino T, Kitamura S, Tomoike H, Hori M, Kitakaze M: A calcium channel blocker activates both ecto-5(′)-nucleotidase and NO synthase in HUVEC. Biochem Biophys Res Commun 2003;311:625-628.
28. Edgell CJ, McDonald CC, Graham JB: Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983;80:3734-3737.
29. Li H, Oehrlein SA, Wallerath T, Ihrig-Biedert I, Wohlfart P, Ulshofer T, Jessen T, Herget T, Forstermann U, Kleinert H: Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene. Mol Pharmacol 1998;53:630-637.
30. Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST: Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:38-44.
31. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H: Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000;87:1195-1201.
32. Waeber B, Burnier M: AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther 2003;1:23-33.
33. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-910.
34. Herbette LG, Rhodes DG, Mason RP: New approaches to drug design and delivery based on drug-membrane interactions. Drug Des Deliv 1991;7:75-118.
35. Weis M, Pehlivanli S, von Scheidt W: Vasodilator response to nifedipine in human coronary arteries with endothelial dysfunction. J Cardiovasc Pharmacol 2002;39:172-180.
36. Young HS, Skita V, Mason RP, Herbette LG: Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism. Biophys J 1992;61:1244-1255.
37. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5.
38. Baykal Y, Yilmaz MI, Celik T, Gok F, Rehber H, Akay C, Kocar IH: Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 2003;21:1207-1211.
39. Scribner AW, Loscalzo J, Napoli C: The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003;482:95-99.
40. Yasunari K, Maeda K, Watanabe T, Nakamura M, Asada A, Yoshikawa J: Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation. J Cardiovasc Pharmacol 2003;42(suppl 1):S55-S60.
41. Matsumoto N, Manabe H, Ochiai J, Fujita N, Takagi T, Uemura M, Naito Y, Yoshida N, Oka S, Yoshikawa T: An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity. Shock 2003;19:547-552.
42. Yayama K, Kunimatsu N, Teranishi Y, Takano M, Okamoto H: Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 2003;1593:231-238.
43. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T: Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003;93:438-447.
44. Watanabe T, Barker TA, Berk BC: Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005;45:163-169.
45. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H: Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003;14(suppl 3):S227-S232.
46. Simonis G, Braun MU, Kirrstetter M, Schon SP, Strasser RH: Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction. J Cardiovasc Pharmacol 2003;41:780-787.
47. Simonis G, Dahlem MH, Hohlfeld T, Yu X, Marquetant R, Strasser RH: A novel activation process of protein kinase C in the remote, nonischemic area of an infarcted heart is mediated by angiotensin-AT1 receptors. J Mol Cell Cardiol 2003;35:1349-1358.
48. Kimura S, Zhang GX, Abe Y: Malfunction of vascular control in lifestyle-related diseases: oxidative stress of angiotensin II-induced hypertension: mitogen-activated protein kinases and blood pressure regulation. J Pharmacol Sci 2004;96:406-410.
49. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T: Antioxidative effect of p38 mitogen-activated protein kinase inhibitor in the kidney of hypertensive rat. J Hypertens 2005;23:165-174.
50. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK: Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004;24:677-683.
51. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR: The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 2005;65:495-504.
52. Griendling KK, Krause KH, Schmidt HHHW (eds): 1st International Conference on NAD(P)H oxidases. Norderstedt, Books on Demand GmbH, 2004.